• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Primary Dysmenorrhea - Pipeline Review, H2 2012 Product Image

Primary Dysmenorrhea - Pipeline Review, H2 2012

  • Published: October 2012
  • 39 pages
  • Global Markets Direct

Primary Dysmenorrhea – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Primary Dysmenorrhea - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Primary Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Primary Dysmenorrhea.
- A review of the Primary Dysmenorrhea products under development by companies and universities/research READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Primary Dysmenorrhea Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Primary Dysmenorrhea 7
Primary Dysmenorrhea Therapeutics under Development by Companies 9
Primary Dysmenorrhea Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Primary Dysmenorrhea Therapeutics – Products under Development by Companies 15
Primary Dysmenorrhea Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Primary Dysmenorrhea Therapeutics Development 17
China Aoxing Pharmaceutical Co., Inc 17
PDC Biotech GmbH 18
Primary Dysmenorrhea – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Peptidometics - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PDC-41 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PDC-31 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
sildenafil citrate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
fenellin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Tongjingshule - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
mefenamic acid - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
peppermint oil - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Omega-3 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Primary Dysmenorrhea Therapeutics - Dormant Products 33
Primary Dysmenorrhea – Product Development Milestones 34
Featured News & Press Releases 34
Jul 19, 2010: Aoxing Pharmaceutical Company Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 34
Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea 34
Jan 05, 2010: China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug 35
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 35
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 36
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 36
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007. 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Primary Dysmenorrhea, H2 2012 7
Products under Development for Primary Dysmenorrhea – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
China Aoxing Pharmaceutical Co., Inc, H2 2012 17
PDC Biotech GmbH, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Primary Dysmenorrhea Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Primary Dysmenorrhea, H2 2012 7
Products under Development for Primary Dysmenorrhea – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos